Athira Pharma’s Phase 2/3 LIFT-AD study wins independent endorsement 

The neurodegeneration-focused biopharma Athira Pharma (Nasdaq:ATHA) will continue its Phase 2/3 LIFT-AD study of fosgonimeton (ATH-1017) in patients with mild-to-moderate Alzheimer’s disease.

The company recently announced an unblinded interim efficacy and futility analysis of LIFT-AD. In addition, an independent data monitoring committee recommended continuing the study of fosgonimeton (ATH-1017) in patients with mild-to-moderate Alzheimer’s disease (AD).

In many ways, the past year has not been kind to Seattle-based Athira. Last October, the company announced that its former CEO Lee Kawas and cofounder would resign in the wake of research misconduct allegations. (Kawas has since established an investment firm known as Propel Bio Partners.) In June 2022, Athira announced disappointing results from the Phase 2 ACT-AD trial involving (ATH-101) in Alzheimer’s disease.

Athira’s share price fell from $34.25 on December 31, 2020 to under $3 per share in…

Read more
  • 0